Heiko Maacke

DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma

Heiko Maacke, Kirsten Jost, Sven Opitz et al. · Oncogene · 2000 · 228 citations

Medicine, Molecular Biology, Oncology +15

Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer

Heiko Maacke, Sven Opitz, Kirsten Jost et al. · International Journal of Cancer · 2000 · 226 citations

Medicine, Genetics, Oncology +15

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with<i>RAS/RAF</i>Alterations

Aditya Bardia, Mrinal M. Gounder, Jordi Rodón et al. · The Oncologist · 2019 · 86 citations · Full text

Medicine, Oncology, Pharmacology +14

A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

Enriqueta Felip, Federico Rojo, Martin Reck et al. · Clinical Cancer Research · 2008 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.

Ryan J. Sullivan, Jeffrey S. Weber, Sapna P. Patel et al. · Journal of Clinical Oncology · 2015 · 59 citations

Medicine, Pharmacology, Pharmacotherapy +13